Romiplostim N01 for Chemotherapy-induced Thrombocytopenia in Tumors: a Prospective Multi-center One-arm Study

NCT07063225 Phase 2 RECRUITING

To evaluate the efficacy and safety of Romiplostim N01 to treat chemotherapy-induced thrombocytopenia in tumors

Details

Lead sponsor	Institute of Hematology & Blood Diseases Hospital, China
Phase	Phase 2
Status	RECRUITING
Enrolment	50
Start date	2025-08
Completion	2026-08

Conditions

• Chemotherapy-induced Thrombocytopenia
• Romiplostim N01

Interventions

• Romiplostim N01

Primary outcomes

• Efficiency after 12 weeks of treatment with Romiplostim N01 — 12 weeks
  The proportion of patients whose platelet count was ≥ 50 × 10\^9/L after 12 weeks (3 months) of treatment with Romiplostim N01.

Countries

China